Johnson & Johnson seeks FDA authorization of Covid booster shot

By Lauren Gardner
A box of Johnson & Johnson vaccines are shown by a pharmacist. | Szilard Koszticsak/AP Photo

Johnson & Johnson on Tuesday asked the Food and Drug Adminstration to authorize a booster dose of its Covid-19 vaccine for people 18 and older.

The company did not specify how long after initial vaccination the second, booster dose should be given. J&J submitted data to the FDA in September it said showed that a booster shot given two to six months after an initial dose bolstered antibody protection against Covid.

J&J said Monday that giving a second dose two months after the first increased protection against symptomatic moderate to severe Covid-19 to 94 percent, with 100 percent protection against severe illness.

"A booster of our COVID-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent," said Mathai Mammen, global head of research and development at J&J's Janssen subsidiary. “At the same time, we continue to recognize that a single-shot COVID-19 vaccine that provides strong and long-lasting protection remains a crucial component to vaccinating the global population.”

The Food and Drug Administration's independent vaccine advisory committee is scheduled to meet on Oct. 15 to consider the J&J booster shot, clearing the way for the agency to make a final decision about whether to authorize its use.

The timing of the meeting is unusual: FDA does not normally announce an advisory panel will gather to discuss an application before one is filed. But the Biden administration is pushing to roll out Covid-19 boosters quickly this fall to prevent a fall or winter surge as temperatures grow colder and people head indoors, including for the holiday season.

The agency has authorized a booster shot from Pfizer and BioNTech for the elderly and for younger adults with jobs or underlying health conditions that increase their risk of severe Covid-19.

Background: J&J's single-dose vaccine has had limited uptake domestically since the federal government paused its use in April over concerns about blood clotting post-inoculation. The company's U.S. production was also interrupted for months by problems at a contractor's plant.

The initial efficacy of the two other vaccines authorized or approved for use in the U.S., Pfizer's and Moderna's messenger RNA products, also has outshone that of Johnson & Johnson's. J&J said earlier this year that a single shot of its vaccine provided 66 percent protection against moderate and severe disease; the mRNA vaccines posted effectiveness rates above 90 percent.

Still, J&J's shot has held up against the highly contagious Delta variant, with the company promoting a small lab study last summer finding robust levels of neutralizing antibodies against the strain in vaccine recipients.

So far, roughly 15 million people have gotten the J&J vaccine, compared to nearly 103 million for Pfizer and about 68 million for Moderna, according to CDC data.

What's next: FDA will consider the booster application over the coming weeks. The next major development will come at the Oct. 15 advisory committee meeting.


What is inkl?

Important stories

See news based on value, not advertising potential. Get the latest news from around the world.

Trusted newsrooms

We bring you reliable news from the world’s most experienced journalists in the most trusted newsrooms.

Ad-free reading

Read without interruptions, distractions or intrusions of privacy.